Clinical efficacy and safety of sodium cantharidinate plus chemotherapy in non‐small‐cell lung cancer: A systematic review and meta‐analysis of 38 randomized controlled trials.

Summary: What is known and objective: Sodium cantharidinate has been widely used in lung cancer treatment in China. To investigate whether sodium cantharidinate improves clinical effectiveness in non‐small‐cell lung cancer, we systematically re‐evaluated all related studies. Methods: All studies of cantharidinate for non‐small‐cell lung cancers (NSCLC) were selected from the MEDLINE, EMBASE, Web of Science (ISI), China National Knowledge Infrastructure Database (CNKI), Chinese Scientific Journals Full‐Text Database (VIP), Wanfang, China Biological Medicine Database (CBM), Cochrane Central Register of Controlled Trials (CENTRAL), Chinese clinical trial registry (Chi‐CTR), WHO International Clinical Trials Registry Platform (WHO‐ICTRP) and US‐clinical trials databases (established to September 2017). Their quality was evaluated using the Cochrane evaluation handbook of randomized controlled trials (RCTs) (5.1.0). The data were extracted following PICO principles and synthesized through meta‐analysis. Results and discussion: We included 38 trials involving 2845 patients, but most trials had an unclear risk of bias. Sodium cantharidinate could increase the objective response rate (ORR) (1.52, (1.40‐1.66]), disease control rate (DCR) (1.20, [1.16‐1.25]) and quality of life (QOL) (1.76, [1.56‐1.98]), but not the 1‐year overall survival (OS) rate (1.16, [0.91‐1.47]) and the 2‐year OS rate (1.21, [0.51‐2.91]). Subgroup analysis revealed that sodium cantharidinate and vitamin B6 at 0.5, 0.4 or 0.3 mg, and cantharidinate at 0.5 mg could all increase the ORR and DCR. Cantharidinate therapy had a lower risk of neutropenia (0.58, [0.50‐0.67]), thrombocytopenia (0.57, [0.45‐0.72]), gastrointestinal reaction (0.65, [0.52‐0.82]) and nausea/vomiting (0.56, [0.41‐0.76]) than that of chemotherapy alone. Sensitivity analysis showed that the results had good robustness. What is new and conclusion: Current evidence reveals that sodium cantharidinate can improve tumour responses and QOL with a lower risk of haematotoxicity and gastrointestinal toxicity than chemotherapy alone in NSCLC. However, the evidence does not indicate that it can improve long‐term survival rates. [ABSTRACT FROM AUTHOR]